pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

18,629 catalysts · 4,728 grant · 3,685 8k filing · 2,621 approval · 2,129 device 510k · 1,725 device recall · 1,490 device pma

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-31: 0 catalysts2026-09-01: 0 catalysts2026-09-02: 0 catalysts2026-09-03: 12 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 1 catalyst2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts2026-11-09: 1 catalyst2026-11-10: 0 catalysts2026-11-11: 0 catalysts2026-11-12: 0 catalysts2026-11-13: 0 catalysts2026-11-14: 0 catalysts2026-11-15: 0 catalysts2026-11-16: 0 catalysts2026-11-17: 0 catalysts2026-11-18: 0 catalysts2026-11-19: 0 catalysts2026-11-20: 0 catalysts2026-11-21: 0 catalysts2026-11-22: 0 catalysts2026-11-23: 0 catalysts2026-11-24: 0 catalysts2026-11-25: 0 catalysts2026-11-26: 0 catalysts2026-11-27: 0 catalysts2026-11-28: 0 catalysts2026-11-29: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
from 2025-08-12×clear all
type
  • grant4,728
  • 8k filing3,685
  • approval2,621
  • device 510k2,129
  • device recall1,725
  • device pma1,490
device adverse event
1,000
  • recall586
  • earnings585
  • phase 2 completion172
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Nov 3, 2025

    50
    ›Nov 5, 2025recall303d agoQuVa Pharma, Inc. recall (Cls II)IGC Pharma, Inc.

    R.E.C.K. (Ropivacaine HCl, EPINEPHrine, CloNIDine HCl, and Ketorolac Tromethamine) in Sodium Chloride Solution, Total Volume: 50 mL syringe. INJECTION FOR PERIARTICULAR USE; Not for IV Use. THIS IS A COMPOUNDED DRUG. QuVA Pharma, 1075 West Park One Drive, Suite 100, Sugar Land, TX 77478. NDC 70092-1433-50 — Reason: Presence of Particulate Matter — Status: Ongoing

    full page →fda recalls ↗
    ›Nov 5, 2025recall303d agoSUN PHARMACEUTICAL INDUSTRIES INC recall (Cls II)TEVA PHARMACEUTICAL INDUSTRIES LTD

    Lisdexamfetamine Dimesylate Capsules, 20 mg, CII, 100-count bottle, Rx only, Manufactured by: OHM Laboratories, New Brunswick, NJ 08901, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, NDC 57664-047-88. — Reason: Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate capsules. — Status: Ongoing

    full page →fda recalls ↗
    ›Nov 5, 2025recall303d agoFARMAKEIO OUTSOURCING LLC recall (Cls II)Transdermal Delivery Solutions Corp

    Testosterone Regular Release 200 MG, 1 PELLET (STERILE) FOR SUBCUTANEOUS INSERTION, RX ONLY, FarmaKeio Outsourcing, 920 S Kimball Ave, Ste 100, Southlake, TX 76092. NDC 73693-0402-01 — Reason: CGMP Deviations: Potential presence of metal particulate matter — Status: Ongoing

    full page →fda recalls ↗
    ›Nov 5, 2025recall303d agoTeva Pharmaceuticals USA, Inc recall (Cls II)Terns Pharmaceuticals, Inc.

    Prazosin Hydrochloride, Capsules, USP, 5 mg, Rx only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, a) 100 Capsules, NDC 0093-4069-01, b) 250 Capsules, NDC 0093-4069-52, c) 500 Capsules, NDC 0093-4069-05 — Reason: CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots. — Status: Ongoing

    full page →fda recalls ↗
    ›Nov 5, 2025recall303d agoSUN PHARMACEUTICAL INDUSTRIES INC recall (Cls II)TEVA PHARMACEUTICAL INDUSTRIES LTD

    Lisdexamfetamine Dimesylate Capsules, 10 mg, CII, 100-count bottle, Rx only, Manufactured by: OHM Laboratories, New Brunswick, NJ 08901, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, NDC 57664-046-88. — Reason: Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate capsules. — Status: Ongoing

    full page →fda recalls ↗
    ›Nov 5, 2025recall303d agoBreckenridge Pharmaceutical, Inc. recall (Cls II)Breckenridge Pharmaceutical Inc

    Duloxetine Delayed-Release Capsules, USP, 60 mg, a.) 90-count bottle (NDC: 51991-748-90), b.)1000-count bottle (NDC 51991-748-10),Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain; Dist. by: Breckenridge Pharmaceutical, Inc., Berkeley Heights, NJ 07922. — Reason: CGMP Deviations: N-nitroso-duloxetine impurity above the safety assessment limit of 12.5ppm. — Status: Ongoing

    full page →fda recalls ↗
    ›Nov 5, 2025recall303d agoEndo USA, Inc. recall (Cls III)Par Pharmaceutical Inc

    Everolimus tablets 10 mg, 28 tablets (each carton contains 4 blister strips with 7 tablets each), Rx only, Manufactured by: Par Pharmaceutical Chestnut Ridge, NY 10977 NDC# 49884-128-91 — Reason: Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C. — Status: Ongoing

    full page →fda recalls ↗
    ›Nov 5, 2025recall303d agoSUN PHARMACEUTICAL INDUSTRIES INC recall (Cls II)TEVA PHARMACEUTICAL INDUSTRIES LTD

    Lisdexamfetamine Dimesylate Capsules, 40 mg, CII, 100-count bottle, Rx only, Manufactured by: OHM Laboratories, New Brunswick, NJ 08901, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, NDC 57664-049-88. — Reason: Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate capsules. — Status: Ongoing

    full page →fda recalls ↗
    ›Nov 5, 2025recall303d agoFARMAKEIO OUTSOURCING LLC recall (Cls II)Transdermal Delivery Solutions Corp

    Testosterone 87.5 MG, 1 PELLET (STERILE) FOR SUBCUTANEOUS INSERTION, RX ONLY, FarmaKeio Outsourcing, 920 S Kimball Ave, Ste 100, Southlake, TX 76092. NDC 73693-0386-01 — Reason: CGMP Deviations: Potential presence of metal particulate matter — Status: Ongoing

    full page →fda recalls ↗
    ›Nov 5, 2025recall303d agoEndo USA, Inc. recall (Cls III)Par Pharmaceutical Inc

    Everolimus tablets 5mg, 28 tablets (each carton contains 4 blister strips with 7 tablets each), Rx only, Manufactured by: Par Pharmaceutical Chestnut Ridge, NY 10977 NDC# 49884-125-91 — Reason: Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C. — Status: Ongoing

    full page →fda recalls ↗
    ›Nov 5, 2025recall303d agoSUN PHARMACEUTICAL INDUSTRIES INC recall (Cls II)TEVA PHARMACEUTICAL INDUSTRIES LTD

    Lisdexamfetamine Dimesylate Capsules, 30 mg, CII, 100-count bottle, Rx only, Manufactured by: OHM Laboratories, New Brunswick, NJ 08901, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, NDC 57664-048-88. — Reason: Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate capsules. — Status: Ongoing

    full page →fda recalls ↗
    ›Nov 5, 2025recall303d agoHeritage Pharmaceuticals Inc recall (Cls II)Hepion Pharmaceuticals, Inc.

    Desipramine Hydrochloride Tablets, USP, 75 mg, 100 count bottle (NDC 23155-581-01), Rx only, Manufactured by: USV Private Limited, Daman, India, Manufactured for: Avet Pharmaceuticals Inc., East Brunswick, NJ 08816. — Reason: CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level. — Status: Ongoing

    full page →fda recalls ↗
    ›Nov 5, 2025device 510k303d agoGlobus Medical, Inc. — ExcelsiusGPS™ Instruments (510k cleared)GLOBUS MEDICAL INC

    Product code: OLO. Advisory committee: Neurology. Type: Traditional

    full page →fda device 510k ↗
    ›Nov 5, 2025device 510k303d agoPoly Medicure Limited — Polyshield Safety IV Catheters (510k cleared)

    Product code: FOZ. Advisory committee: General Hospital. Type: Special

    full page →fda device 510k ↗
    ›Nov 5, 2025device 510k303d agoPhasor Health, LLC — EVAC-MRI (510k cleared)

    Product code: JXG. Advisory committee: Neurology. Type: Traditional

    full page →fda device 510k ↗
    ›Nov 5, 2025device 510k303d agoWaldemar Link GmbH & Co. KG — Allure Hip Stem and Intramedullary Plugs (510k cleared)

    Product code: MEH. Advisory committee: Orthopedic. Type: Traditional

    full page →fda device 510k ↗
    ›Nov 5, 2025device 510k303d agoViatherm Therapeutics, LLC — ViVY (510k cleared)VLP Therapeutics LLC

    Product code: IMJ. Advisory committee: Physical Medicine. Type: Traditional

    full page →fda device 510k ↗
    ›Nov 5, 2025device 510k303d agoBeijing Sinovation Medical Technology Co., Ltd. — Depth Electrode (RSDE-08); Depth Electrode (RSDE-10); Depth Electrode (RSDE-12); Depth Electrode (RSDE-14); Depth Electrode (RSDE-16); Depth Electrode (RSDE-16F); Depth Electrode (RSDE-08S); Depth Electrode (RSDE-10S); Depth Electrode (RSDE-12S); Depth Electrode (RSDE-14S); Depth Electrode (RSDE-16S); Depth Electrode (RSDE-16G); Depth Electrode (RSDE-18); Depth Electrode (RSDE-18F); Depth Electrode (RSDE-18T); Depth Electrode (RSDE-20); Depth Electrode (RSDE-20F); Dept (510k cleared)

    Product code: GZL. Advisory committee: Neurology. Type: Traditional

    full page →fda device 510k ↗
    ›Nov 5, 2025device pma303d agoPromega Corporation — OncoMate® MSI Dx Analysis System (PMA)

    Product code: SFL. Advisory committee: MG. Decision: APPR

    full page →fda device pma ↗
    ›Nov 5, 2025device recall303d agoCepheid device recall (Cls II)

    Xpert MTB/RIF. Model Number: GXMTB/RIF-US-10. — Reason: Product testing did not meet expected stability criteria. — Status: Ongoing

    full page →fda device recalls ↗
    ›Nov 5, 2025device recall303d agoDiasol, Inc device recall (Cls II)

    Brand Name: Diasol Product Name: 100425-10-DEX100, Liquid Concentrate for Bicarbonate Dialysis Non Pyrogenic, 2K, 3.0CA, 1.0MG, 208.2 liters — Reason: Safety and efficacy of dialysis acid concentrate cannot be assured — Status: Ongoing

    full page →fda device recalls ↗
    ›Nov 5, 2025device recall303d agoDiasol, Inc device recall (Cls II)

    Brand Name: Diasol Product Name: 100225-10-DEX100, Liquid Concentrate for Bicarbonate Dialysis Non Pyrogenic, 2K, 3.0CA, 1.0MG, 208.2 liters — Reason: Safety and efficacy of dialysis acid concentrate cannot be assured — Status: Ongoing

    full page →fda device recalls ↗
    ›Nov 5, 2025device recall303d agoDiasol, Inc device recall (Cls II)

    Brand Name: Diasol Product Name: 100220-10-DEX100, Liquid Concentrate for Bicarbonate Dialysis Non Pyrogenic, 2K, 3.0CA, 1.0MG, 208.2 liters — Reason: Safety and efficacy of dialysis acid concentrate cannot be assured — Status: Ongoing

    full page →fda device recalls ↗
    ›Nov 5, 2025device recall303d agoDiasol, Inc device recall (Cls II)

    Brand Name: Diasol Product Name: 100325-10-DEX100, Liquid Concentrate for Bicarbonate Dialysis Non Pyrogenic, 2K, 3.0CA, 1.0MG, 208.2 liters — Reason: Safety and efficacy of dialysis acid concentrate cannot be assured — Status: Ongoing

    full page →fda device recalls ↗
    ›Nov 5, 2025device recall303d agoAccriva Diagnostics, Inc. device recall (Cls II)Co-Diagnostics, Inc.

    Hemochron Activated Clotting Time Low-Range Test Cuvette, REF: ACT-LR, to be used with the Hemochron Signature ELITE Whole Blood Microcoagulation System — Reason: Test cuvettes, used with an assay for monitoring heparin anticoagulation, may have a foreign object that has sharp edges and could pose a risk of injury if not detected prior to handling. — Status: Ongoing

    full page →fda device recalls ↗
    ›Nov 5, 2025device recall303d agoDiasol, Inc device recall (Cls II)

    Brand Name: Diasol Product Name: 100125-10-DEX100, Liquid Concentrate for Bicarbonate Dialysis Non Pyrogenic, 2K, 3.0CA, 1.0MG, 208.2 liters — Reason: Safety and efficacy of dialysis acid concentrate cannot be assured — Status: Ongoing

    full page →fda device recalls ↗
    ›Nov 5, 2025device recall303d agoDiasol, Inc device recall (Cls II)

    Brand Name: Diasol Product Name: 100230-10-DEX100, Liquid Concentrate for Bicarbonate Dialysis Non Pyrogenic, 2K, 3.0CA, 1.0MG, 208.2 liters — Reason: Safety and efficacy of dialysis acid concentrate cannot be assured — Status: Ongoing

    full page →fda device recalls ↗
    ›Nov 6, 2025approval302d agoDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval(daratumumab + hyaluronidase (human recombinant))

    Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

    full page →(daratumumab + hyaluronidase (human recombinant)) →fda approvals ↗
    ›Nov 6, 2025approval302d agoVOQUEZNA (VONOPRAZAN FUMARATE) — FDA approvalvonoprazan fumarate

    Sponsor: PHATHOM. Form: TABLET. Route: ORAL

    full page →vonoprazan fumarate →fda approvals ↗
    ›Nov 6, 2025approval302d agoSUMATRIPTAN SUCCINATE — FDA approvalSUMATRIPTAN SUCCINATE

    Sponsor: ALEMBIC. Form: INJECTABLE. Route: SUBCUTANEOUS

    full page →SUMATRIPTAN SUCCINATE →fda approvals ↗
    ›Nov 6, 2025approval302d agoSIMLANDI (ADALIMUMAB-RYVK) — FDA approvalAlvotech

    Sponsor: ALVOTECH USA INC. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Nov 6, 2025approval302d agoBUPROPION HYDROCHLORIDE — FDA approvalIpca Pharmaceuticals Inc

    Sponsor: PH HEALTH. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Nov 6, 2025approval302d agoBUPROPION HYDROCHLORIDE — FDA approvalBUPROPION HYDROCHLORIDE

    Sponsor: HERITAGE PHARMA. Form: TABLET. Route: ORAL

    full page →BUPROPION HYDROCHLORIDE →fda approvals ↗
    ›Nov 6, 2025approval302d agoBUPROPION HYDROCHLORIDE — FDA approvalIpca Pharmaceuticals Inc

    Sponsor: CHARTWELL RX. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Nov 6, 2025approval302d agoPIPERACILLIN (PIPERACILLIN SODIUM) — FDA approvalIstituto Biochimico Italiano Giovanni Lorenzini Spa

    Sponsor: ISTITUTO BIO ITA SPA. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Nov 6, 2025approval302d agoCETRORELIX ACETATE — FDA approvalEMD Serono Inc

    Sponsor: TEVA PHARMS INC. Form: POWDER. Route: SUBCUTANEOUS

    full page →fda approvals ↗
    ›Nov 6, 2025approval302d agoCETRORELIX ACETATE — FDA approvalEMD Serono Inc

    Sponsor: TEVA PHARMS INC. Form: POWDER. Route: SUBCUTANEOUS

    full page →fda approvals ↗
    ›Nov 6, 2025approval302d agoBUPROPION HYDROCHLORIDE — FDA approvalBUPROPION HYDROCHLORIDE

    Sponsor: SANDOZ. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →BUPROPION HYDROCHLORIDE →fda approvals ↗
    ›Nov 6, 2025approval302d agoPIPERACILLIN (PIPERACILLIN SODIUM) — FDA approvalIstituto Biochimico Italiano Giovanni Lorenzini Spa

    Sponsor: ISTITUTO BIO ITA SPA. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Nov 6, 2025approval302d agoDOXYCYCLINE HYCLATE — FDA approvalPolyPid Ltd.

    Sponsor: STERISCIENCE. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Nov 6, 2025approval302d agoDASATINIB — FDA approvalDASATINIB

    Sponsor: ALEMBIC. Form: TABLET. Route: ORAL

    full page →DASATINIB →fda approvals ↗
    ›Nov 6, 2025approval302d agoBUPROPION HYDROCHLORIDE — FDA approvalBUPROPION HYDROCHLORIDE

    Sponsor: ALEMBIC. Form: TABLET. Route: ORAL

    full page →BUPROPION HYDROCHLORIDE →fda approvals ↗
    ›Nov 6, 2025approval302d agoBUPROPION HYDROCHLORIDE — FDA approvalSciegen Pharmaceuticals Inc

    Sponsor: SCIEGEN PHARMS. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Nov 6, 2025approval302d agoNELARABINE — FDA approvalNELARABINE

    Sponsor: AMNEAL. Form: INJECTABLE. Route: INTRAVENOUS

    full page →NELARABINE →fda approvals ↗
    ›Nov 6, 2025approval302d agoBUPROPION HYDROCHLORIDE — FDA approvalBUPROPION HYDROCHLORIDE

    Sponsor: HERITAGE PHARMA. Form: TABLET. Route: ORAL

    full page →BUPROPION HYDROCHLORIDE →fda approvals ↗
    ›Nov 6, 2025approval302d agoBUPROPION HYDROCHLORIDE — FDA approvalInvaGen Pharmaceuticals Inc

    Sponsor: INVAGEN PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Nov 6, 2025approval302d agoBUPROPION HYDROCHLORIDE — FDA approvalIpca Pharmaceuticals Inc

    Sponsor: ACTAVIS LABS FL INC. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Nov 6, 2025device 510k302d agoVenus Concept, Inc. — Venus Nova (FP-2001) (510k cleared)

    Product code: GEI. Advisory committee: General, Plastic Surgery. Type: Traditional

    full page →fda device 510k ↗
    ›Nov 6, 2025device 510k302d agoMotive Health, Inc. — Motive™ Muscle Stimulator for Lower Back (OT01-1003) (510k cleared)

    Product code: NGX. Advisory committee: Physical Medicine. Type: Traditional

    full page →fda device 510k ↗
    ›Nov 6, 2025device 510k302d agoAdaptix Limited — Adaptix Ortho350 (510k cleared)

    Product code: IZF. Advisory committee: Radiology. Type: Traditional

    full page →fda device 510k ↗
    ← prev
    page 111 of 373
    next →
    $IGC0.2670+0.41%
    $TERN52.95-0.03%
    $TEVA37.49+3.59%
    $TEVA37.49+3.59%
    $PHAT9.2600-1.38%
    $CODX1.51000.00%
    $HEPA
    $TEVA37.49+3.59%
    $ALVO5.3450+2.00%
    $TEVA37.49+3.59%
    $GMED79.93+1.27%
    $AMRX18.06+2.15%
    $PYPD5.3000-0.56%